Please login to the form below

Not currently logged in
Email:
Password:

basal insulin

This page shows the latest basal insulin news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf

This would allow its use in combination with basal insulin, where the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.

Latest news

  • Novo says real-world data backs its insulin switching Novo says real-world data backs its insulin switching

    Novo Nordisk's battle for supremacy in the basal insulin sector opened another front over the weekend as the firm presented real-world evidence of the superiority of its Tresiba brand. ... It showed that switching to Tresiba (insulin from another basal

  • Sanofi to develop a mobile app for insulin patients Sanofi to develop a mobile app for insulin patients

    Sanofi to develop a mobile app for insulin patients. Will work with therapeutic companion software company Voluntis. ... The tool, which Sanofi characterises as a ‘digital insulin titration solution’, will be a mobile app that assists type 2 diabetes

  • Type 2 diabetes can be reversed in just four months, say researchers Type 2 diabetes can be reversed in just four months, say researchers

    calorie intake by 500 to 750 per day and continued use of glucose-controlling drugs (metformin, acarbose and in some cases basal insulin) to closely manage blood sugar levels. ... According to lead investigator Hertzel Gerstein, the team chose to use

  • Sanofi wins EU approval for new diabetes combination Suliqua Sanofi wins EU approval for new diabetes combination Suliqua

    The long-acting basal insulin and GLP-1 agonist is already on the market in the US as Soliqua, having been approved by the FDA in November last year on the ... same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination

  • Sanofi launches insulin combo Soliqua in US Sanofi launches insulin combo Soliqua in US

    Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... The two rival drugs are once-daily injections which combine a long-acting basal insulin with a GLP-1

More from news
Approximately 0 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. “ ... We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan.

  • Going the distance Going the distance

    The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    ORBIT (Observational Registry for Basal Insulin Treatment) is a study focused on type 2 diabetes in China and the result of Sanofi's partnership with the CDS and George Institute for ... The company sees particular potential for Lyxumia as a combination

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics